An international collaboration has published groundbreaking research, shedding light on the most significant increase in complexity in the history of life's evolution on Earth: the origin of the ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.

Abstract: Cell segmentation in Phase-Contrast (PhC) microscopy is crucial for non-invasive analysis of live-cell imaging data. However, traditional segmentation methods often struggle with challenges ...

Ociperlimab is described as a humanised immunoglobulin G1 (IgG1) monoclonal antibody with the potential to enhance T cell-mediated immune responses ... "BeiGene halts ociperlimab amid poor Phase III ...

Ociperlimab is described as a humanised immunoglobulin G1 (IgG1) monoclonal antibody with the potential to enhance T cell-mediated immune ... ociperlimab amid poor Phase III trial predictions ...

The primary objective was to determine the recommended Phase 2 dose (RP2D) and optimal dosing regimen for CX-4945. Among 22 patients eligible for efficacy analysis: Three laBCC patients achieved ...

to initiate a global registration Phase 3 study of linperlisib versus physicians' choice of standard of care for the treatment of relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). FDA's ...

Nevertheless, such observations are complex─they require delicate samples kept in the liquid phase, low electron dose, and proper cell viability verification methods. Despite being highly demanding, ...

First, the cell debris and fixation artifacts were gated out. Subsequently, the cell populations were quantified at the G0/G1, S, and G2/M phases using the ModFit software. The aim of this experiment ...

A pen­ny stock biotech re­port­ed that its acute graft-ver­sus-host dis­ease drug failed a late-stage tri­al, but it still plans to seek ac­cel­er­at­ed ap­proval.

Candel's clinical development program for CAN-2409 includes completed phase 2a clinical trials in both non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), as well as a ...